Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
02/25/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 20k | $1.60 | $32k | | 02/25/2022 |
02/09/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 30k | $2.55 | $76.6k | | 02/08/2022 |
02/08/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 1000 | $2.54 | $2.5k | | 02/08/2022 |
02/07/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 42.1k | $2.61 | $109.8k | By Trust | 02/04/2022 |
02/07/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 42.1k | $2.61 | $109.8k | Trust | 02/04/2022 |
02/04/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 2k | $2.45 | $4.9k | | 02/04/2022 |
02/04/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 7.9k | $2.31 | $18.3k | By Trust | 02/04/2022 |
02/04/2022 | REVELATION BIOSCIENCES, INC. | | Purchase | Common Stock | 7.9k | $2.31 | $18.3k | Trust | 02/04/2022 |
09/19/2019 | Odonate Therapeutics, Inc. | ODT | Exercise | Common Stock | 77.3k | $0.00 | $0 | | 09/19/2019 |
09/19/2019 | Odonate Therapeutics, Inc. | ODT | Exercise | Common Stock | 74k | $0.00 | $0 | | 09/19/2019 |
09/19/2019 | Odonate Therapeutics, Inc. | ODT | Exercise | Incentive Units | 78.8k | $0.54 | $42.6k | | 09/19/2019 |
09/19/2019 | Odonate Therapeutics, Inc. | ODT | Exercise | Incentive Units | 75.4k | $0.54 | $40.7k | | 09/19/2019 |
04/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 2 | $6.09 | $12.2 | | 04/15/2019 |
04/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 2 | $7.16 | $14.3 | | 04/15/2019 |
03/29/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 94 | $5.47 | $514.2 | | 03/29/2019 |
03/29/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 94 | $6.43 | $604.4 | | 03/29/2019 |
03/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 195 | $6.49 | $1.3k | | 03/15/2019 |
03/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 195 | $7.64 | $1.5k | | 03/15/2019 |
02/28/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 261 | $4.85 | $1.3k | | 02/28/2019 |
02/28/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 261 | $5.70 | $1.5k | | 02/28/2019 |
02/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 239 | $5.30 | $1.3k | | 02/15/2019 |
02/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 239 | $6.23 | $1.5k | | 02/15/2019 |
01/31/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 246 | $5.13 | $1.3k | | 01/31/2019 |
01/31/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 246 | $6.04 | $1.5k | | 01/31/2019 |
01/23/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 174k | $5.99 | $1M | | 01/23/2019 |
01/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 874 | $5.74 | $5k | | 01/15/2019 |
01/15/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 874 | $6.75 | $5.9k | | 01/15/2019 |
01/07/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Purchase | Common Stock | 82 | $5.85 | $479.7 | | 01/07/2019 |
01/07/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Purchase | Common Stock | 287 | $5.85 | $1.7k | | 01/07/2019 |
01/07/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Purchase | Common Stock | 98 | $5.85 | $573.3 | | 01/07/2019 |
01/07/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Purchase | Common Stock | 397 | $5.85 | $2.3k | | 01/07/2019 |
01/07/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Purchase | Common Stock | 700 | $5.85 | $4.1k | | 01/07/2019 |
01/07/2019 | LA JOLLA PHARMACEUTICAL CO | LJPC | Purchase | Common Stock | 436 | $5.85 | $2.6k | | 01/07/2019 |
12/31/2018 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Common Stock | 154 | $8.02 | $1.2k | | 12/31/2018 |
12/31/2018 | LA JOLLA PHARMACEUTICAL CO | LJPC | Grant | Stock Option (Right to Buy) | 154 | $9.43 | $1.5k | | 12/31/2018 |
|